BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.

Abstract

We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs and PET revealed marked tumor reduction with gradual neurological improvement and permanent panhypopituitarism.

DOI: 10.2217/cns-2016-0034

Cite this paper

@article{Roque2017BRAFV600EMP, title={BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.}, author={Ashley M Roque and Yazm{\'i}n Odia}, journal={CNS oncology}, year={2017}, volume={6 2}, pages={95-99} }